Versant Ventures launches biotechnology firm Jecure Therapeutics
Versant Ventures has launched Jecure Therapeutics, a biotechnology firm focused on the discovery of novel therapeutics to treat non-alcoholic steatohepatitis (NASH) and liver fibrosis.
Versant Ventures has launched Jecure Therapeutics, a biotechnology firm focused on the discovery of novel therapeutics to treat non-alcoholic steatohepatitis (NASH) and liver fibrosis.
X-Chem has expanded its collaboration with Janssen Biotech for the discovery of new drug leads for inflammatory disease treatment.
Eli Lilly and Company has updated label of its once-weekly Trulicity (dulaglutide) to include use in combination with basal insulin for adults with Type 2 diabetes.
Prexton Therapeutics has closed a €29m Series B round led by Forbion Capital Partners and Seroba Life Sciences.
The US Federal Trade Commission (FTC) has charged that Shire ViroPharma abused government processes via serial, sham petitioning to delay generics and maintain its monopoly over Vancocin HCl Capsules.
Acticor Biotech, a bio-pharmaceutical company focused on the treatment of acute ischemic stroke, has raised €1,5m from CapDecisif Management.
Biotechnology company Chondrial Therapeutics, focused on the treatment of rare mitochondrial diseases, has secured up to $22.6m in Series A financing led by Deerfield Management besides naming a new president and CEO in Carole Ben-Maimon, MD.
Soligenix has secured Promising Innovative Medicine (PIM) designation from the UK Medicines and Healthcare Products Regulatory Agency for SGX301 (synthetic hypericin) to treat cutaneous T-cell lymphoma (CTCL).
Tarveda Therapeutics has raised $30m in series D financing to advance pentarin miniaturized drug conjugates.
Neurotrope has signed a licensing agreement with Stanford University for an accelerated synthesis of Alzheimer's drug bryostatin-1.